Bryozoan Metabolites and Their Pharmacological Activities

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (10 March 2022) | Viewed by 376

Special Issue Editors

National Research Council (CNR) - Institute of Biomolecular Chemistry (ICB), Pozzuoli, Italy
Interests: natural product chemistry; bioactivity; spectroscopy
Special Issues, Collections and Topics in MDPI journals
National Research Council (CNR) - Institute of Biomolecular Chemistry (ICB), Pozzuoli, Italy
Interests: marine natural compounds; marine ecology; drug discovery; organic chemistry; NMR
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The phylum Bryozoa comprises ~6000 described extant species from freshwater and marine environment. Despite this great biodiversity, the chemistry of this group has been poorly investigated in comparison with other invertebrates. Indeed, only 26 species have been investigated to date, revealing ca 300 molecules, indicating bryozoans as a rich source of novel chemical entities, only partially screened. In addition, most of the bryozoans compounds isolated so far, including the well-known bryostatins, have shown a wide spectra of pharmacological properties such as anticancer, antiparasitic, antiviral, and neurological activities, suggesting significant biomedical potential. 

To increase interest in this underexplored group of organisms, the Special Issue “Bryozoan Metabolites and their Pharmacological Activities” will collect original papers, as well as reviews, focused on bryozoans natural product chemistry and bioactivity. Studies on bryozoans symbionts are welcome too.

Dr. Maria Letizia Ciavatta
Dr. Marianna Carbone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Bryozoa
  • Natural products chemistry
  • Drug discovery
  • Novel therapeutic agents
  • Bioactivity profiling
  • Drug design
  • Chemical synthesis

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop